Mandate

Vinge advises Nordea and UBS in relation to Sanitec’s listing on NASDAQ OMX Stockholm

November 29, 2013

Vinge advises Nordea Bank AB (publ) and UBS Limited – joint global coordinators and bookrunners – in relation to Sanitec Oyj:s application for listing on NASDAQ OMX Stockholm. Sanitec’s principal shareholder is EQT. A prospectus was published on 27 November and the first day of trading on NASDAQ OMX Stockholm is expected to be 10 December.  

EQT may increase the offer and have also granted, among others, Nordea and UBS a customary over-allotment option. The total value of the offering amounts to approximately SEK 2.4 billion. Assuming the offering is increased in full, the total value of the offering amounts to approximately SEK 3.1 billion (and approximately SEK 3.6 billion assuming the over-allotment option is also exercised in full).  

Sanitec is the market leader in bathroom ceramics and a leading supplier of bathroom fixtures in its core markets (Belgium, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Poland, Russia, Sweden, Ukraine, and the United Kingdom). Sanitec has leading positions (number one or two based on volume) in bathroom ceramics in 12 of its 13 core markets and command a strong position in growth markets, including Russia. Sanitec’s unique brand portfolio includes many of the longest-established and most well-known brands on the European bathroom fixtures market, including its ‘‘national jewels’’: Ifö® (Sweden and Denmark), Ido® (Finland and Sweden), Keramag® (Germany), Sphinx® (the Netherlands), Twyford® (United Kingdom), Allia® (France), Pozzi-Ginori® (Italy), Kolo® (Poland) and Colombo® (Ukraine). In 2012, Sanitec’s net sales amounted to EUR 752.8 million and the number of employees amounted to approximately 6,500.  

Vinge’s team consisted mainly of Peter Bäärnhielm and David Andersson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025